Asoprisnil
Appearance
From Wikipedia, the free encyclopedia
This is the current revision of this page, as edited by Ffffrr (talk | contribs) at 01:10, 26 April 2022 (Importing Wikidata short description: "Chemical compound" (Shortdesc helper)). The present address (URL) is a permanent link to this version.
Revision as of 01:10, 26 April 2022 by Ffffrr (talk | contribs) (Importing Wikidata short description: "Chemical compound" (Shortdesc helper))
(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Chemical compound
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H35NO4 |
Molar mass | 449.591 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids.[1] In 2005, phase III clinical trials were discontinued due to endometrial changes in patients.[2]
See also
[edit]References
[edit]- ^ DeManno D, Elger W, Garg R, et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids. 68 (10–13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995. S2CID 23074350.
- ^ Schering Interim Report Q1-3 2005
PRTooltip Progesterone receptor |
| ||||||
---|---|---|---|---|---|---|---|
mPRTooltip Membrane progesterone receptor (PAQRTooltip Progestin and adipoQ receptor) |
| ||||||
![]() | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Hidden categories: